Tokyo Tape
Sign in
← Toho Holdings

Quarterly report · Q2

8129.TEDINET S100PLCG
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
MetricValuePeriodScopeSource row
Revenue¥679.7bn2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥1.27T2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥620.8bn2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥4.1bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥1.9bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥7.4bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥18.2bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥4.8bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥6.0bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥5.1bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥3.6bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥13.4bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥3.3bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥3.6bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥3.3bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥740.6bnat 2022-09-30Cons.Assets
Total assets¥702.4bnat 2022-03-31Cons.Assets
Total assets¥695.9bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥495.0bnat 2022-09-30Cons.Liabilities
Total liabilities¥461.1bnat 2022-03-31Cons.Liabilities
Net assets / equity¥245.6bnat 2022-09-30Cons.Net assets
Net assets / equity¥241.3bnat 2022-03-31Cons.Net assets
Net assets / equity¥240.7bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥102.1bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥94.3bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥97.9bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥90.0bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥97.1bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥88.9bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥10.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥16.3bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥11.6bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥407m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥11.0bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.4bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥3.0bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥4.5bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥2.2bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥51.012022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥21.792022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥189.72021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥46.392021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥21.842021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥46.882022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥174.482021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥42.622021-04-01 → 2021-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio33.1%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio34.3%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio34.5%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 46
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥28.3bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥28.3bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥850m
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue2022-04-01 → 2022-09-30¥45.1bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue external2022-04-01 → 2022-09-30¥45.1bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3m
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentsegment profit2022-04-01 → 2022-09-30¥878m
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue2022-04-01 → 2022-09-30¥4.8bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.1bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3.7bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentsegment profit2022-04-01 → 2022-09-30¥478m
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue2022-04-01 → 2022-09-30¥654.8bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue external2022-04-01 → 2022-09-30¥631.0bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥23.8bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentsegment profit2022-04-01 → 2022-09-30¥3.3bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥3.3bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥2.5bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥782m
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥246m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥708.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥679.7bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥28.3bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥4.9bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥28.3bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥28.3bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥996m
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue2021-04-01 → 2021-09-30¥45.5bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue external2021-04-01 → 2021-09-30¥45.4bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥5m
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.3bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue2021-04-01 → 2021-09-30¥4.0bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue external2021-04-01 → 2021-09-30¥819m
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥3.2bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentsegment profit2021-04-01 → 2021-09-30¥312m
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue2021-04-01 → 2021-09-30¥597.0bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue external2021-04-01 → 2021-09-30¥572.6bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥24.4bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.1bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥2.7bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥2.0bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥667m
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥100m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥649.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥620.8bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-09-30¥28.3bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥2.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 580
ItemContextValueUnit
Ordinary incomePrior1YTDDuration4802000000JPY
Ordinary incomeCurrentYTDDuration7392000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration64000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration109000000JPY
Other eiPrior1YTDDuration511000000JPY
Other eiCurrentYTDDuration40000000JPY
Extraordinary incomePrior1YTDDuration575000000JPY
Extraordinary incomeCurrentYTDDuration149000000JPY
Loss on disposal of noncurrent assets elPrior1YTDDuration59000000JPY
Loss on disposal of noncurrent assets elCurrentYTDDuration74000000JPY
Impairment loss elPrior1YTDDuration12000000JPY
Impairment loss elCurrentYTDDuration26000000JPY
Provision for loss on anti monopoly act elPrior1YTDDuration－JPY
Provision for loss on anti monopoly act elCurrentYTDDuration1400000000JPY
Other elPrior1YTDDuration235000000JPY
Other elCurrentYTDDuration28000000JPY
Extraordinary lossPrior1YTDDuration306000000JPY
Extraordinary lossCurrentYTDDuration1529000000JPY
Income before income taxesPrior1YTDDuration5071000000JPY
Income before income taxesCurrentYTDDuration6012000000JPY
Income taxes currentPrior1YTDDuration2383000000JPY
Income taxes currentCurrentYTDDuration2801000000JPY
Income taxes deferredPrior1YTDDuration-599000000JPY
Income taxes deferredCurrentYTDDuration-399000000JPY
Income taxesPrior1YTDDuration1783000000JPY
Income taxesCurrentYTDDuration2401000000JPY
Profit lossPrior1YTDDuration3288000000JPY
Profit lossCurrentYTDDuration3611000000JPY
Profit loss attributable to non controlling interestsPrior1YTDDuration16000000JPY
Profit loss attributable to non controlling interestsCurrentYTDDuration12000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration3271000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration3598000000JPY
Profit lossPrior1YTDDuration3288000000JPY
Profit lossCurrentYTDDuration3611000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration809000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration2005000000JPY
Share of other comprehensive income of associates accounted for using equity method ociPrior1YTDDuration21000000JPY
Share of other comprehensive income of associates accounted for using equity method ociCurrentYTDDuration40000000JPY
Other comprehensive incomePrior1YTDDuration830000000JPY
Other comprehensive incomeCurrentYTDDuration2045000000JPY
Comprehensive incomePrior1YTDDuration4119000000JPY
Comprehensive incomeCurrentYTDDuration5656000000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration4102000000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration5643000000JPY
Comprehensive income attributable to non controlling interestsPrior1YTDDuration16000000JPY
Comprehensive income attributable to non controlling interestsCurrentYTDDuration12000000JPY
Income before income taxesPrior1YTDDuration5071000000JPY
Income before income taxesCurrentYTDDuration6012000000JPY
Depreciation and amortization ope cfPrior1YTDDuration3262000000JPY
Depreciation and amortization ope cfCurrentYTDDuration2919000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass